In a phase 3 trial, researchers from the University of Toronto in Toronto, Canada, evaluated the safety and efficacy of sotagliflozin in adults with type 2 diabetes and stage 3 chronic kidney disease. The primary objective was the superiority of HbA1c reductions at week 26 with sotagliflozin compared to placebo. At 26 weeks, the placebo-adjusted mean change in HbA1c was -0.1% and -0.2% in the sotagliflozin 200 and 400 mg groups, respectively, indicating a significant reduction. Urine albumin creatinine ratio was also reduced with both doses, but changes were not sustained at week 52. Adverse events, including serious adverse events, were comparable between the treatment groups.
Sotagliflozin 400 mg Significantly Reduces HbA1c in Adults with Type 2 Diabetes and Stage 3 Chronic Kidney Disease
Researchers have found that sotagliflozin 400 mg significantly reduced HbA1c compared with placebo after 26 weeks in adults with type 2 diabetes and stage 3 chronic kidney disease. They also noted a reduction of urine albumin creatinine ratio at 26 weeks with each of the two doses.
Latest from Blog
Doctors may have found the key to solving the enigmatic issue of bacterial vaginosis through studying
New research reveals that the phases of a heartbeat have a considerable impact on brain and
In mid-July, viewers were amazed as a SpaceX rocket launch in Arizona created a mesmerizing aurora-like
Three-toed fossil footprints, dating back over 210 million years, have been found embedded in soft mud.
NASCAR has secured a new media rights deal starting in 2025, with Fox Sports and NBC
